

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 021044-004600US

Assistant Commissioner for Patents
Box DAC
Washington, D.C. 20231

On

August 8, 2002

TOWNSEND and TOWNSEND and CREW LLP

By:

John Xare

7/A
JM
10/24/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

CONAWAY *et al.*

Application No.: 09/914,324

Filed: Herewith

For: NOVEL COMPONENT OF VON
HIPPEL-LINDAU TUMOR
SUPPRESSOR COMPLEX AND SCF
UBIQUITIN LIGASE

Examiner: Not yet assigned

Art Unit: Not yet assigned

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

U.S. Patent and Trademark Office
Box SEQUENCE
P.O. Box 2327
Arlington, VA 22202

Sir:

In response to the request to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) mailed October 30, 2001, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.